It has been suggested that estradiol and oxytocin (OT) may interact as neuroendocrine components in the regulation of sexual behavior. In the present study the effect of estradiol benzoate (EB) treatment (50 µg/kg body weight/2 days) on [3H]-OT binding was evaluated in adult and 21-day-old gonadectomized male and female rat brains. Coronal sections through the ventromedial nucleus of the hypothalamus (VMN) were analyzed in three different section planes. EB priming induced an increase in [3H]-OT binding in the VMN of both male and female rats. Greater binding site density and significant EB effects were found in the most caudal plane where the ventrolateral portion of the VMN is well defined at both ages. OT binding in the central amygdaloid nucleus was not affected by this treatment but higher binding levels were found in the most caudal sections irrespective of hormonal status or sex. No sex differences were detected in OTbinding in the VMN of basal or EB-treated animals. These results suggest that a dose of EB which activates female sexual behavior in female but not in male rats is able to induce similar levels of OT binding in the VMN of animals of both sexes.

Keywords:
Oxytocin receptors, Ventromedial hypothalamic nucleus, Estradiol
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.